Recent events
Recent events tied to this brand in public sources.
Back to profile10 entries
2022
Sartorius raises 2022 sales growth forecast
Sartorius updated its 2022 sales revenue forecast after the acquisition, raising expected consolidated sales growth to about 15% to 19%, from about 14% to 18%.
2022
Sartorius completes acquisition of Novasep chromatography business
Sartorius announced that its subsidiary Sartorius Stedim Biotech completed the acquisition of Novasep’s chromatography business on February 7, 2022, after receiving approval from the U.S. Federal Trade Commission.
2022
Sartorius completes acquisition of Novasep chromatography division
Sartorius, through its subgroup Sartorius Stedim Biotech, closed its acquisition of Novasep's chromatography division on February 7, 2022, following approval by the U.S. Federal Trade Commission.
2021
Sartorius acquires Xell AG
Sartorius, through its subgroup Sartorius Stedim Biotech, acquired Xell AG, a cell culture media specialist.
2021
Sartorius and Wujiahe Gene Technology sign strategic cooperation agreement
Sartorius and Wujiahe Gene Technology signed a strategic cooperation agreement in Beijing to jointly develop a GMP-compliant gene therapy viral-vector production platform and provide process-technology training for industry professionals.
2021
RoosterBio and Sartorius sign strategic collaboration
RoosterBio and Sartorius announced a strategic collaboration to advance the scale-up of human mesenchymal stem/stromal cell manufacturing for regenerative medicine, combining their technologies and systems.
2020
Sartorius launches Incucyte SX5
Sartorius launched the Incucyte SX5 Live-Cell Analysis System, a new live-cell analysis product with up to five fluorescence channels.
2020
Sartorius introduces BioPAT Spectro
Sartorius introduced BioPAT Spectro, a tool for Raman spectroscopy analysis with its ambr automated bioreactor systems and BIOSTAT STR single-use production bioreactors.
2020
Sartorius introduces BioPAT Spectro
Sartorius introduced BioPAT Spectro, a Quality by Design tool for use with its ambr automated micro and mini bioreactor systems and BIOSTAT STR single-use production bioreactors.
2019
Danaher announces sale of life sciences businesses to Sartorius
Danaher announced that it had signed an agreement to sell certain life sciences businesses to Sartorius AG for $750 million. The businesses include biomolecular characterization, chromatography hardware and resins, and microcarriers and particle validation standards.